LEXICON PHARMACEUTICALS, INC. Deferred Tax Assets, Operating Loss Carryforwards, State and Local
LEXICON PHARMACEUTICALS, INC. (LXRX) had Deferred Tax Assets, Operating Loss Carryforwards, State and Local of $86.90 million as of 2022-12-31, per its 10-K filed 2023-03-03.
Discontinued › Notes › Income Taxes › Deferred Tax Assets, Gross › Deferred Tax Assets, Operating Loss Carryforwards, Components
us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal · last filed 2023-03-03
- 2022-12-31: Deferred Tax Assets, Operating Loss Carryforwards, State and Local $86.90M.
- 2021-12-31: Deferred Tax Assets, Operating Loss Carryforwards, State and Local $86.90M.
- 2020-12-31: Deferred Tax Assets, Operating Loss Carryforwards, State and Local $86.90M.
- 2019-12-31: Deferred Tax Assets, Operating Loss Carryforwards, State and Local $83.00M.
| Period end | Deferred Tax Assets, Operating Loss Carryforwards, State and Local |
|---|---|
| 2022-12-31 | $86.90M 10-K · filed 2023-03-03 |
| 2021-12-31 | $86.90M 10-K · filed 2022-03-10 |
| 2020-12-31 | $86.90M 10-K · filed 2021-03-12 |
| 2019-12-31 | $83.00M 10-K · filed 2020-03-12 |
| 2018-12-31 | $455.80M 10-K · filed 2019-03-15 |
| 2017-12-31 | $382.00M 10-K · filed 2018-03-01 |
| 2016-12-31 | $315.40M 10-K · filed 2017-03-06 |
| 2015-12-31 | $455.10M 10-K · filed 2016-03-11 |
| 2014-12-31 | $460.20M 10-K · filed 2015-03-12 |
| 2013-12-31 | $444.10M 10-K · filed 2014-03-07 |
| 2012-12-31 | $394.30M 10-K · filed 2013-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |